Targeted Oncology

, Volume 11, Issue 5, pp 569–577

Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer

  • Alessandra Modena
  • Roberto Iacovelli
  • Aldo Scarpa
  • Matteo Brunelli
  • Chiara Ciccarese
  • Emanuela Fantinel
  • Davide Bimbatti
  • Francesco Massari
  • Guido Martignoni
  • Giampaolo Tortora
Review Article

DOI: 10.1007/s11523-016-0450-9

Cite this article as:
Modena, A., Iacovelli, R., Scarpa, A. et al. Targ Oncol (2016) 11: 569. doi:10.1007/s11523-016-0450-9

Abstract

Despite the development of novel effective therapeutic strategies, metastatic castration-resistant prostate cancer (mCRPC) remains a disease with a lethal course and a high biological and molecular heterogeneity. To date, germline mutations in the BRCA gene represent one of the main risk factors for developing prostate cancer, with a strong association with aggressive phenotype and poor clinical outcomes. A better understanding of the genomic landscape of prostate cancer has strengthened the idea that “synthetic lethality” of this disease might be useful in cancer-drug discovery, focusing on agents such as platinum compounds and poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi). In this review, we summarize the main data available on BRCA mutations and discuss the clinical implications of these genomic aberrations in the management of prostate cancer, stressing the need to identify prognostic and predictive biomarkers and to deeply understand the mechanisms of treatment resistance, in order to maximize personalized medicine protocols and therefore clinical benefit.

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Alessandra Modena
    • 1
  • Roberto Iacovelli
    • 1
  • Aldo Scarpa
    • 2
  • Matteo Brunelli
    • 2
  • Chiara Ciccarese
    • 1
  • Emanuela Fantinel
    • 1
  • Davide Bimbatti
    • 1
  • Francesco Massari
    • 3
  • Guido Martignoni
    • 4
  • Giampaolo Tortora
    • 1
  1. 1.Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata (AOUI)University of VeronaVeronaItaly
  2. 2.Department of Pathology and Diagnostics, Azienda Ospedaliera Universitaria Integrata (AOUI)University of VeronaVeronaItaly
  3. 3.Division of OncologyS. Orsola-Malpighi HospitalBolognaItaly
  4. 4.Department of PathologyCasa di Cura PederzoliVeronaItaly

Personalised recommendations